Effect of EGFR-TKI retreatment following chemotherapy for ad-vanced non-small cell lung cancer patients who underwent EG-FR-TKI
10.3969/j.issn.1000-8179.20141231
- VernacularTitle:化疗后再使用EGFR-TKI治疗晚期非小细胞肺癌的临床研究
- Author:
Guohao XIA
;
Yvn ZENG
;
Ying FANG
;
Shaorong YU
;
Li WANG
;
Meiqi SHI
;
Weili SUN
;
Xinen HUANG
;
Jia CHEN
;
Jifeng FENG
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
epidermal growth factor receptor tyrosine kinase inhibitor;
erlotinib;
gefitinib;
chemotherapy;
acquired resistance
- From:
Chinese Journal of Clinical Oncology
2014;(22):1454-1458
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations have higher response rate and more prolonged survival following treatment with single-agent EGFR tyrosine kinase inhibitor (EGFR-TKI) compared with patients with wild-type EGFR. However, all patients treated with reversible inhibitors develop acquired re-sistance over time. The mechanisms of resistance are complicated. The lack of established therapeutic options for patients after a failed EGFR-TKI treatment poses a great challenge to physicians in managing this group of lung cancer patients. This study evaluates the in-fluence of EGFR-TKI retreatment following chemotherapy after failure of initial EGFR-TKI within at least six months on NSCLC pa-tients. Methods:The data of 27 patients who experienced treatment failure from their initial use of EGFR-TKI within at least 6 months were analyzed. After chemotherapy, the patients were retreated with EGFR-TKI (gefitinib 250 mg qd or erlotinib 150 mg qd), and the tumor progression was observed. The patients were assessed for adverse events and response to therapy. Targeted tumor lesions were as-sessed with CT scan. Results:Of the 27 patients who received EGFR–TKI retreatment, 1 (3.7%) patient was observed in complete re-sponse (CR), 8 (29.6%) patients in partial response (PR), 14 (51.9%) patients in stable disease (SD), and 4 (14.8%) patients in progres-sive disease (PD). The disease control rate (DCR) was 85.2%(95%CI=62%-94%). The median progression-free survival (mPFS) was 6 months (95%CI=1-29). Of the 13 patients who received the same EGFR-TKI, 1 patient in CR, 3 patients in PR, 8 patients in SD, and 2 patients in PD were observed. The DCR was 84.6%, and the mPFS was 5 months. Of the 14 patients who received another EG-FR-TKI, 0 patient in CR, 6 patients in PR, 6 patients in SD, and 2 patients in PD were observed. The DCR was 85.7%, and the mPFS was 9.5 months. Significant difference was found between the 2 groups in progression-free survival but not in response rate or disease control rate. Conclusion:Retreatment of EGFR-TKIs can be considered an option after failure of chemotherapy for patients who were
previously controlled by EGFR-TKI treatment.
